Zmynd11基因是一种在生物医学领域备受关注的基因,它编码的蛋白质在多个生物学过程中发挥着关键作用。Zmynd11是一种转录共抑制因子,主要通过与组蛋白H3.3结合来调控基因表达。它还涉及多种疾病的发生机制,包括神经发育障碍和癌症等。本文将基于现有的研究,对Zmynd11基因进行综述。
Zmynd11基因编码的蛋白质在神经发育中发挥重要作用。研究表明,Zmynd11的突变与多种神经发育障碍相关,如智力障碍、自闭症和癫痫等。Zmynd11突变会导致蛋白质功能的丧失,进而影响神经发育和功能。例如,Zmynd11突变会导致智力障碍、发育迟缓、行为异常和癫痫等症状[1,2,5,6,7,8]。这些症状表明Zmynd11在神经发育中具有重要作用,其突变可能导致神经发育障碍的发生。
Zmynd11基因的突变也与癌症的发生密切相关。研究表明,Zmynd11在多种癌症中表达下调,包括前列腺癌、急性髓系白血病和结直肠癌等。Zmynd11表达下调可能与肿瘤细胞生长、迁移和侵袭等过程有关。例如,Zmynd11表达下调会导致HNRNPA1在细胞质中形成应激颗粒,进而促进肿瘤细胞的生长和侵袭[4]。此外,Zmynd11-MBTD1融合蛋白可以导致NuA4/TIP60组蛋白乙酰转移酶复合物在基因编码区域异常定位,从而影响基因转录和肿瘤发生[9]。
除了在神经发育和癌症中的作用,Zmynd11还涉及其他生物学过程。研究表明,Zmynd11参与组蛋白H3.3的磷酸化过程,进而影响基因转录和表观遗传调控[3]。此外,Zmynd11还可以与多种蛋白质相互作用,如SETD2、HNRNPA1和PRMT5等,从而影响基因表达和生物学过程。
综上所述,Zmynd11基因在多个生物学过程中发挥着重要作用,包括神经发育、癌症发生和表观遗传调控等。Zmynd11的突变和表达改变可能导致多种疾病的发生,包括神经发育障碍和癌症等。进一步研究Zmynd11的生物学功能和疾病发生机制,有助于深入理解生物学过程和疾病发生机制,为疾病的治疗和预防提供新的思路和策略。
参考文献:
1. Yates, Thabo M, Drucker, Morgan, Barnicoat, Angela, Tan, Wen-Hann, Balasubramanian, Meena. 2020. ZMYND11-related syndromic intellectual disability: 16 patients delineating and expanding the phenotypic spectrum. In Human mutation, 41, 1042-1050. doi:10.1002/humu.24001. https://pubmed.ncbi.nlm.nih.gov/32097528/
2. Coe, Bradley P, Witherspoon, Kali, Rosenfeld, Jill A, Romano, Corrado, Eichler, Evan E. 2014. Refining analyses of copy number variation identifies specific genes associated with developmental delay. In Nature genetics, 46, 1063-71. doi:10.1038/ng.3092. https://pubmed.ncbi.nlm.nih.gov/25217958/
3. Armache, Anja, Yang, Shuang, Martínez de Paz, Alexia, Li, Haitao, Josefowicz, Steven Z. 2020. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. In Nature, 583, 852-857. doi:10.1038/s41586-020-2533-0. https://pubmed.ncbi.nlm.nih.gov/32699416/
4. Lian, Cheng, Zhang, Chunyi, Tian, Pan, Cheng, Jingdong, Wei, Gong-Hong. 2024. Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity. In Signal transduction and targeted therapy, 9, 258. doi:10.1038/s41392-024-01961-7. https://pubmed.ncbi.nlm.nih.gov/39341825/
5. Huynh, Minh-Tuan, Tran, Cong Toai, Joubert, Madeleine, Bénéteau, Claire. 2021. Intragenic Deletion of the ZMYND11 Gene in 10p15.3 is Associated with Developmental Delay Phenotype: A Case Report. In Cytogenetic and genome research, 161, 445-448. doi:10.1159/000518689. https://pubmed.ncbi.nlm.nih.gov/34818214/
6. Oates, Stephanie, Absoud, Michael, Goyal, Sushma, Basson, M Albert, Pal, Deb K. 2021. ZMYND11 variants are a novel cause of centrotemporal and generalised epilepsies with neurodevelopmental disorder. In Clinical genetics, 100, 412-429. doi:10.1111/cge.14023. https://pubmed.ncbi.nlm.nih.gov/34216016/
7. Tumiene, Birute, Čiuladaitė, Ž, Preikšaitienė, E, Utkus, A, Kučinskas, V. 2017. Phenotype comparison confirms ZMYND11 as a critical gene for 10p15.3 microdeletion syndrome. In Journal of applied genetics, 58, 467-474. doi:10.1007/s13353-017-0408-3. https://pubmed.ncbi.nlm.nih.gov/28933030/
8. Bodetko, Aleksandra, Chrzanowska, Joanna, Rydzanicz, Malgorzata, Ploski, Rafal, Smigiel, Robert. 2024. Further Delineation of Clinical Phenotype of ZMYND11 Variants in Patients with Neurodevelopmental Dysmorphic Syndrome. In Genes, 15, . doi:10.3390/genes15020256. https://pubmed.ncbi.nlm.nih.gov/38397245/
9. Devoucoux, Maëva, Fort, Victoire, Khelifi, Gabriel, Hussein, Samer M I, Côté, Jacques. . Oncogenic ZMYND11-MBTD1 fusion protein anchors the NuA4/TIP60 histone acetyltransferase complex to the coding region of active genes. In Cell reports, 39, 110947. doi:10.1016/j.celrep.2022.110947. https://pubmed.ncbi.nlm.nih.gov/35705031/